Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases.

about

Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases.

Item

http://www.wikidata.org/entity/Q42705635

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Chemo-Immunotherapy Using Lent ...... Cancer with Liver Metastases.

@en

Chemo-Immunotherapy Using Lent ...... Cancer with Liver Metastases.

@nl

type

Item

label

Chemo-Immunotherapy Using Lent ...... Cancer with Liver Metastases.

@en

Chemo-Immunotherapy Using Lent ...... Cancer with Liver Metastases.

@nl

prefLabel

Chemo-Immunotherapy Using Lent ...... Cancer with Liver Metastases.

@en

Chemo-Immunotherapy Using Lent ...... Cancer with Liver Metastases.

@nl

P1476

Chemo-Immunotherapy Using Lent ...... Cancer with Liver Metastases.

@en

P2093

Hiroko Ina

http://www.w3.org/2001/XMLSchema#string

Kenji Ina

http://www.w3.org/2001/XMLSchema#string

Masahiko Yoneda

http://www.w3.org/2001/XMLSchema#string

Ryuichi Furuta

http://www.w3.org/2001/XMLSchema#string

Satoshi Kayukawa

http://www.w3.org/2001/XMLSchema#string

Takae Kataoka

http://www.w3.org/2001/XMLSchema#string

P2860

The use of lentinan for treating gastric cancer

Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.

P31

scholarly article

P356

10.3390/MEDSCI4020008

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29083372

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5635777

http://www.w3.org/2001/XMLSchema#string